Clinical Trials List
Protocol NumberCLCL161A2201
2012-10-22 - 2014-07-29
Phase II
Terminated3
-
Trial Applicant
NOVARTIS (TAIWAN) CO., LTD.
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2025/08/20
Investigators and Locations
Co-Principal Investigator
- SUNG-HSIN KUO Division of Hematology & Oncology
- 郭文宏 Division of General Surgery
- YEN-SHEN LU Division of Hematology & Oncology
- 林璟宏 Division of Hematology & Oncology
- 羅喬 Division of General Surgery
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- 金光亮 Division of General Surgery
- Chun-Yu Liu Division of Hematology & Oncology
- Yi-Fang Tsai Division of General Surgery
- 賴亦貞 Division of Radiology
- Ta-Chung Chao Division of Hematology & Oncology
- 邱仁輝 Division of General Surgery
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- Yung-Chang Lin Division of Hematology & Oncology
- Wen-Ling Kuo Division of General Surgery
- 沈士哲 Division of General Surgery
- Chi-Chang Yu Division of General Surgery
The Actual Total Number of Participants Enrolled
0 Terminated
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
6 participants
-
Global
100 participants
